COVID-19: consider cytokine storm syndromes and immunosuppression

COVID-19: consider cytokine storm syndromes and immunosuppression. Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., & Manson, J. J. The Lancet, 395(10229):1033–1034, March, 2020.

Paper doi abstract bibtex

1-liner: This correspondence letter published in The Lancet recommends identifying and treating hyperinflammation, such as secondary HLH, in severe COVID-19.

Summary

Article type – correspondence letter

Main takeaways:

Severe COVID-19 disease appears to be associated with a cytokine profile resembling secondary HLH, “characterized by increased interleukin (IL)-2, IL-7, granulocyte-colony stimulating factor, interferon-γ inducible protein 10, monocyte chemo-attractant protein 1, macrophage inflammatory protein 1-α, and tumour necrosis factor-α”
Elevated ferritin and IL-6, which may suggest “hyperinflammation,” were found to be predictors of fatality from a retrospective study of 150 COVID-19 cases in Wuhan
Immunosuppressive agents such as glucocorticoids, IVIG, tocilizumab, anakinra, and JAK inhibitors could be considered for treatment in patients with evidence of hyperinflammation

@article{mehta_covid-19_2020,
	title = {{COVID}-19: consider cytokine storm syndromes and immunosuppression},
	volume = {395},
	issn = {0140-6736, 1474-547X},
	shorttitle = {{COVID}-19},
	url = {https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30628-0/abstract},
	doi = {10.1016/S0140-6736(20)30628-0},
	abstract = {<p><u>1-liner</u>: This correspondence letter published in The Lancet recommends identifying and treating hyperinflammation, such as secondary HLH, in severe COVID-19.</p>
<p>\&nbsp;</p>
<p><u>Summary</u></p>
<p>Article type \&ndash; correspondence letter</p>
<p>Main takeaways:</p>
<ul>
<li>Severe COVID-19 disease appears to be associated with a cytokine profile resembling secondary HLH, \&ldquo;characterized by increased interleukin (IL)-2, IL-7, granulocyte-colony stimulating factor, interferon-\&gamma; inducible protein 10, monocyte chemo-attractant protein 1, macrophage inflammatory protein 1-\&alpha;, and tumour necrosis factor-\&alpha;\&rdquo;</li>
<li> Elevated ferritin and IL-6, which may suggest \&ldquo;hyperinflammation,\&rdquo; were found to be predictors of fatality from a retrospective study of 150 COVID-19 cases in Wuhan</li>
<li> Immunosuppressive agents such as glucocorticoids, IVIG, tocilizumab, anakinra, and JAK inhibitors could be considered for treatment in patients with evidence of hyperinflammation</li>
</ul>
<p>\&nbsp;</p>},
	language = {English},
	number = {10229},
	urldate = {2020-04-25},
	journal = {The Lancet},
	author = {Mehta, Puja and McAuley, Daniel F. and Brown, Michael and Sanchez, Emilie and Tattersall, Rachel S. and Manson, Jessica J.},
	month = mar,
	year = {2020},
	pmid = {32192578},
	keywords = {Shradha Kulkarni},
	pages = {1033--1034},
	annote = {1-liner: This correspondence letter published in The Lancet recommends identifying and treating hyperinflammation, such as secondary HLH, in severe COVID-19. 
 
Summary
Article type – correspondence letter
Main takeaways:
-        Severe COVID-19 disease appears to be associated with a cytokine profile resembling secondary HLH, “characterized by increased interleukin (IL)-2, IL-7, granulocyte-colony stimulating factor, interferon-γ inducible protein 10, monocyte chemo-attractant protein 1, macrophage inflammatory protein 1-α, and tumour necrosis factor-α”
-         Elevated ferritin and IL-6, which may suggest “hyperinflammation,” were found to be predictors of fatality from a retrospective study of 150 COVID-19 cases in Wuhan
-        Immunosuppressive agents such as glucocorticoids, IVIG, tocilizumab, anakinra, and JAK inhibitors could be considered for treatment in patients with evidence of hyperinflammation
 },
	file = {Snapshot:C\:\\Users\\mdwan\\Zotero\\storage\\SQE4P4Q2\\Mehta et al. - 2020 - COVID-19 consider cytokine storm syndromes and im.html:text/html}
}

Downloads: 0

{"_id":"cTbqmfJRaojX4fCGH","bibbaseid":"mehta-mcauley-brown-sanchez-tattersall-manson-covid19considercytokinestormsyndromesandimmunosuppression-2020","authorIDs":[],"author_short":["Mehta, P.","McAuley, D. F.","Brown, M.","Sanchez, E.","Tattersall, R. S.","Manson, J. J."],"bibdata":{"bibtype":"article","type":"article","title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","issn":"0140-6736, 1474-547X","shorttitle":"COVID-19","url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30628-0/abstract","doi":"10.1016/S0140-6736(20)30628-0","abstract":"1-liner: This correspondence letter published in The Lancet recommends identifying and treating hyperinflammation, such as secondary HLH, in severe COVID-19.   Summary Article type – correspondence letter Main takeaways: <ul> <li>Severe COVID-19 disease appears to be associated with a cytokine profile resembling secondary HLH, “characterized by increased interleukin (IL)-2, IL-7, granulocyte-colony stimulating factor, interferon-γ inducible protein 10, monocyte chemo-attractant protein 1, macrophage inflammatory protein 1-α, and tumour necrosis factor-α”</li> <li> Elevated ferritin and IL-6, which may suggest “hyperinflammation,” were found to be predictors of fatality from a retrospective study of 150 COVID-19 cases in Wuhan</li> <li> Immunosuppressive agents such as glucocorticoids, IVIG, tocilizumab, anakinra, and JAK inhibitors could be considered for treatment in patients with evidence of hyperinflammation</li> </ul>  ","language":"English","number":"10229","urldate":"2020-04-25","journal":"The Lancet","author":[{"propositions":[],"lastnames":["Mehta"],"firstnames":["Puja"],"suffixes":[]},{"propositions":[],"lastnames":["McAuley"],"firstnames":["Daniel","F."],"suffixes":[]},{"propositions":[],"lastnames":["Brown"],"firstnames":["Michael"],"suffixes":[]},{"propositions":[],"lastnames":["Sanchez"],"firstnames":["Emilie"],"suffixes":[]},{"propositions":[],"lastnames":["Tattersall"],"firstnames":["Rachel","S."],"suffixes":[]},{"propositions":[],"lastnames":["Manson"],"firstnames":["Jessica","J."],"suffixes":[]}],"month":"March","year":"2020","pmid":"32192578","keywords":"Shradha Kulkarni","pages":"1033–1034","annote":"1-liner: This correspondence letter published in The Lancet recommends identifying and treating hyperinflammation, such as secondary HLH, in severe COVID-19. Summary Article type – correspondence letter Main takeaways: - Severe COVID-19 disease appears to be associated with a cytokine profile resembling secondary HLH, “characterized by increased interleukin (IL)-2, IL-7, granulocyte-colony stimulating factor, interferon-γ inducible protein 10, monocyte chemo-attractant protein 1, macrophage inflammatory protein 1-α, and tumour necrosis factor-α” - Elevated ferritin and IL-6, which may suggest “hyperinflammation,” were found to be predictors of fatality from a retrospective study of 150 COVID-19 cases in Wuhan - Immunosuppressive agents such as glucocorticoids, IVIG, tocilizumab, anakinra, and JAK inhibitors could be considered for treatment in patients with evidence of hyperinflammation ","file":"Snapshot:C\\:\\\\Users\\\\mdwan\\\\Zotero\\\\storage\\\\SQE4P4Q2\\\\Mehta et al. - 2020 - COVID-19 consider cytokine storm syndromes and im.html:text/html","bibtex":"@article{mehta_covid-19_2020,\n\ttitle = {{COVID}-19: consider cytokine storm syndromes and immunosuppression},\n\tvolume = {395},\n\tissn = {0140-6736, 1474-547X},\n\tshorttitle = {{COVID}-19},\n\turl = {https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30628-0/abstract},\n\tdoi = {10.1016/S0140-6736(20)30628-0},\n\tabstract = {1-liner: This correspondence letter published in The Lancet recommends identifying and treating hyperinflammation, such as secondary HLH, in severe COVID-19.\n\\ \nSummary\nArticle type \\– correspondence letter\nMain takeaways:\n<ul>\n<li>Severe COVID-19 disease appears to be associated with a cytokine profile resembling secondary HLH, \\“characterized by increased interleukin (IL)-2, IL-7, granulocyte-colony stimulating factor, interferon-\\γ inducible protein 10, monocyte chemo-attractant protein 1, macrophage inflammatory protein 1-\\α, and tumour necrosis factor-\\α\\”</li>\n<li> Elevated ferritin and IL-6, which may suggest \\“hyperinflammation,\\” were found to be predictors of fatality from a retrospective study of 150 COVID-19 cases in Wuhan</li>\n<li> Immunosuppressive agents such as glucocorticoids, IVIG, tocilizumab, anakinra, and JAK inhibitors could be considered for treatment in patients with evidence of hyperinflammation</li>\n</ul>\n\\ },\n\tlanguage = {English},\n\tnumber = {10229},\n\turldate = {2020-04-25},\n\tjournal = {The Lancet},\n\tauthor = {Mehta, Puja and McAuley, Daniel F. and Brown, Michael and Sanchez, Emilie and Tattersall, Rachel S. and Manson, Jessica J.},\n\tmonth = mar,\n\tyear = {2020},\n\tpmid = {32192578},\n\tkeywords = {Shradha Kulkarni},\n\tpages = {1033--1034},\n\tannote = {1-liner: This correspondence letter published in The Lancet recommends identifying and treating hyperinflammation, such as secondary HLH, in severe COVID-19. \n \nSummary\nArticle type – correspondence letter\nMain takeaways:\n- Severe COVID-19 disease appears to be associated with a cytokine profile resembling secondary HLH, “characterized by increased interleukin (IL)-2, IL-7, granulocyte-colony stimulating factor, interferon-γ inducible protein 10, monocyte chemo-attractant protein 1, macrophage inflammatory protein 1-α, and tumour necrosis factor-α”\n- Elevated ferritin and IL-6, which may suggest “hyperinflammation,” were found to be predictors of fatality from a retrospective study of 150 COVID-19 cases in Wuhan\n- Immunosuppressive agents such as glucocorticoids, IVIG, tocilizumab, anakinra, and JAK inhibitors could be considered for treatment in patients with evidence of hyperinflammation\n },\n\tfile = {Snapshot:C\\:\\\\Users\\\\mdwan\\\\Zotero\\\\storage\\\\SQE4P4Q2\\\\Mehta et al. - 2020 - COVID-19 consider cytokine storm syndromes and im.html:text/html}\n}\n\n","author_short":["Mehta, P.","McAuley, D. F.","Brown, M.","Sanchez, E.","Tattersall, R. S.","Manson, J. J."],"key":"mehta_covid-19_2020","id":"mehta_covid-19_2020","bibbaseid":"mehta-mcauley-brown-sanchez-tattersall-manson-covid19considercytokinestormsyndromesandimmunosuppression-2020","role":"author","urls":{"Paper":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30628-0/abstract"},"keyword":["Shradha Kulkarni"],"downloads":0},"bibtype":"article","biburl":"https://drive.google.com/uc?export=download&id=15Z16d0MJ9Ghingm8BA-jsQxRQYUmDrfC","creationDate":"2020-04-27T18:21:57.382Z","downloads":0,"keywords":["shradha kulkarni"],"search_terms":["covid","consider","cytokine","storm","syndromes","immunosuppression","mehta","mcauley","brown","sanchez","tattersall","manson"],"title":"COVID-19: consider cytokine storm syndromes and immunosuppression","year":2020,"dataSources":["tkZRi4L6NmTQxQifD"]}